Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in Asian patients with nAMD (EXTEND III)
NCT00470678Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2007
- Primary completion
- Nov 2008
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Started Jun 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00470678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00470678.